It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Decreased expression of mitochondrial frataxin (FXN) causes Friedreich’s ataxia (FRDA), a neurodegenerative disease with type 2 diabetes (T2D) as severe comorbidity. Brown adipose tissue (BAT) is a mitochondria-enriched and anti-diabetic tissue that turns excess energy into heat to maintain metabolic homeostasis. Here we report that the FXN knock-in/knock-out (KIKO) mouse shows hyperlipidemia, reduced energy expenditure and insulin sensitivity, and elevated plasma leptin, recapitulating T2D-like signatures. FXN deficiency leads to disrupted mitochondrial ultrastructure and oxygen consumption as well as lipid accumulation in BAT. Transcriptomic data highlights cold intolerance in association with iron-mediated cell death (ferroptosis). Impaired PKA-mediated lipolysis and expression of genes controlling mitochondrial metabolism, lipid catabolism and adipogenesis were observed in BAT of KIKO mice as well as in FXN-deficient T37i brown and primary adipocytes. Significant susceptibility to ferroptosis was observed in adipocyte precursors that showed increased lipid peroxidation and decreased glutathione peroxidase 4. Collectively our data point to BAT dysfunction in FRDA and suggest BAT as promising therapeutic target to overcome T2D in FRDA.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Rome Tor Vergata, via della Ricerca Scientifica, Department Biology, Rome, Italy (GRID:grid.6530.0) (ISNI:0000 0001 2300 0941)
2 University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnologies, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X)
3 University of Rome Tor Vergata, Department of Systems Medicine, Rome, Italy (GRID:grid.6530.0) (ISNI:0000 0001 2300 0941)
4 University Campus Bio-Medico, Unit of Microscopic and Ultrastructural Anatomy, Rome, Italy (GRID:grid.9657.d) (ISNI:0000 0004 1757 5329)
5 University of Rome Tor Vergata, Interdepartmental Service Center-Station for Animal Technology (STA), Rome, Italy (GRID:grid.6530.0) (ISNI:0000 0001 2300 0941)
6 IRCCS Bambino Gesù Children’s Hospital, Unit of Neuromuscular and Neurodegenerative Diseases, Rome, Italy (GRID:grid.414125.7) (ISNI:0000 0001 0727 6809)
7 University of Rome Tor Vergata, via della Ricerca Scientifica, Department Biology, Rome, Italy (GRID:grid.6530.0) (ISNI:0000 0001 2300 0941); IRCCS Fondazione Santa Lucia, Rome, Italy (GRID:grid.417778.a) (ISNI:0000 0001 0692 3437)